The novel coronavirus outbreak has reported to be rapidly spreading across the countries and becomes a foremost community health alarm. At present, no vaccine or specific drug is on hand for the treatment of this infectious disease. This review investigates the drugs, which are being evaluated and found to be effective against nCOVID-19 infection. A thorough literature search was performedon the recently published research papers in between January 2020 to May 2020, through various databases like “Science Direct”, “Google Scholar”, “PubMed”,“Medline”, “Web of Science”, and “World Health Organization (WHO)”. We reviewed and documented the information related with the current and future aspects for the management and cure of COVID-19. As of 21st July 2020 a total of 14,562,550 confirmed cases of coronavirus and 607,781 deaths have been reported world-wide. The main clinical feature of COVID-19 ranges from asymptomatic disease to mild lower respiratory tract illness to severe pneumonia, acute lung injury, acute respiratory distress syndrome (ARDS), multiple organ dysfunction, and death. The drugs at present used in COVID-19 patients and ongoing clinical trials focusing on drug repurposing of various therapeutic classes of drug e.g. antiviral, anti-inflammatory and/or immunomodulatory drugs along with adjuvant/supportive care. Many drugs on clinical trials shows effective results on preliminary scale and now used currently in patients. Adjuvant/supportive care therapy are used in patients to get the best results in order to minimize the short and long-term complications. However, further studies and clinical trials are needed on large scale of population to reach any firm conclusion in terms of its efficacy and safety.

据报道，新型冠状病毒的爆发正在各国迅速蔓延，并成为最重要的社区健康警报。目前，尚无治疗这种传染病的疫苗或特效药物。本次审查对这些药物进行了调查，这些药物正在接受评估并被发现可有效对抗 nCOVID-19 感染。通过“Science Direct”、“Google Scholar”、“PubMed”、“Medline”、“Web of Science”和“World”等各种数据库，对2020年1月至2020年5月最近发表的研究论文进行了彻底的文献检索。卫生组织（WHO）”。我们审查并记录了与 COVID-19 的当前和未来管理和治疗相关的信息。截至 2020 年 7 月 21 日，全球共报告新冠病毒确诊病例 14,562,550 例，死亡 607,781 例。COVID-19的主要临床特征包括无症状疾病、轻度下呼吸道疾病、严重肺炎、急性肺损伤、急性呼吸窘迫综合征（ARDS）、多器官功能障碍和死亡。目前用于 COVID-19 患者的药物和正在进行的临床试验侧重于各种治疗类别药物的药物再利用，例如抗病毒、抗炎和/或免疫调节药物以及辅助/支持治疗。许多药物在临床试验中显示出初步有效的结果，目前已用于患者。对患者进行辅助/支持护理治疗以获得最佳结果，从而最大限度地减少短期和长期并发症。然而，还需要在大规模人群中进行进一步的研究和临床试验，才能就其有效性和安全性得出明确的结论。